ImmunityBio Gestione
Criteri Gestione verificati 2/4
ImmunityBio Il CEO è Rich Adcock, nominato in Oct2020, e ha un mandato di 5.83 anni. la retribuzione annua totale è $ 12.72M, composta da 6.5% di stipendio e 93.5% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.053% delle azioni della società, per un valore di $ 4.10M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 5.1 anni e 6 anni.
Informazioni chiave
Rich Adcock
Amministratore delegato
US$12.7m
Compenso totale
| Percentuale dello stipendio del CEO | 6.54% |
| Mandato del CEO | 5.8yrs |
| Proprietà del CEO | 0.05% |
| Durata media del management | 5.1yrs |
| Durata media del Consiglio di amministrazione | 6yrs |
Aggiornamenti recenti sulla gestione
Recent updates
IBRX: FDA Review Timeline For Bladder Cancer Will Drive Future Upside
Analysts have reset their price target on ImmunityBio from $23 to $15. This reflects updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions.ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold
Summary ImmunityBio (IBRX) remains rated Hold as its $8bn+ valuation relies on future clinical and regulatory milestones, not current fundamentals. Anktiva's clinical data in NMIBC and NSCLC is encouraging, but competition is intense and label expansion is critical for long-term upside. Q1 2026 revenues reached $44.2m, but heavy operating losses and cash burn highlight the need for significant revenue ramp or new funding. Key risks include 'key man' dependence on Dr. Soon Shiong, lack of 2026 guidance, and the need for US approvals beyond NMIBC. Read the full article on Seeking Alpha
IBRX: Saudi Rollout And FDA Label Review Will Drive Future Upside
Analysts have raised their ImmunityBio price target from $11.00 to $12.00, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the key drivers of the revision. What’s in the News for ImmunityBio ImmunityBio shares recently reached a 3 month high, with investors focused on July catalysts including the commercial rollout of Anktiva in Saudi Arabia and upcoming updates on second quarter sales performance.
IBRX: Potential Index Inclusion Will Support Cancer Franchise Expansion
Analysts have lowered their ImmunityBio price target slightly from $13.50 to $13.00 as they refresh assumptions around discount rates, revenue growth, margins, and future P/E expectations. What’s in the News for ImmunityBio Retail traders are speculating that ImmunityBio stock could shift from the Russell 2000 to the Russell 1000 based on a cutoff around US$5.7b, with some traders expecting potential index fund buying and changes in volatility if inclusion occurs, according to recent Stocktwits sentiment data and after hours trading moves.Here's What Analysts Are Forecasting For ImmunityBio, Inc. (NASDAQ:IBRX) After Its First-Quarter Results
Shareholders of ImmunityBio, Inc. ( NASDAQ:IBRX ) will be pleased this week, given that the stock price is up 15% to...Expanded Immunotherapy Platform And Automation Will Transform Long Term Earnings Power
Catalysts About ImmunityBio ImmunityBio is a clinical stage immunotherapy company focused on using its IL-15 based ANKTIVA platform, natural killer cell therapies, and DNA vaccine vectors to treat cancer and immune related conditions. What are the underlying business or industry changes driving this perspective?Single Asset Dependence And Regulatory Hurdles Will Gradually Give Way To Broader Platform Potential
Catalysts About ImmunityBio ImmunityBio develops immunotherapy treatments that use cytokines, cell therapies, and DNA vaccines to target cancer and immune dysfunction. What are the underlying business or industry changes driving this perspective?Global Immunotherapy Expansion And AI Automation Will Reshape Long Term Prospects
Catalysts About ImmunityBio ImmunityBio is a commercial stage immunotherapy company focused on ANKTIVA and a broader platform of cytokine, cell therapy, and DNA vaccine candidates for oncology and immune related conditions. What are the underlying business or industry changes driving this perspective?ImmunityBio Q1 Earnings Preview: I Fear A Selloff, But Am Long-Term Bullish
Summary ImmunityBio, Inc.'s stock has significantly declined despite my previous "Buy" ratings, primarily due to a $100m fundraising and market selloff in December. Founder Dr. Patrick Soon-Shiong's vision for Anktiva as a groundbreaking cancer therapy remains strong, with promising data and potential label expansions in multiple oncology fields. Short-term concerns include high cash burn, premium pricing, and BCG shortages, which may lead to a stock selloff after Q1 earnings. Long-term optimism persists for IBRX stock due to Anktiva's "best-in-class" data and potential for significant market cap growth, despite immediate financial challenges. Read the full article on Seeking AlphaImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Summary ImmunityBio faces significant operational risks due to reliance on international BCG supplies and competition from Adstiladrin in NMIBC treatment. Financially, ImmunityBio struggles with high cash burn, limited cash runway, and substantial debt, despite backing from billionaire founder Dr. Patrick Soon-Shiong. Anktiva's market adoption is uncertain beyond NMIBC, with potential hurdles in expanding to other indications like NSCLC, ovarian cancer, and TNBC. Despite Anktiva's potential, IBRX remains a "sell" due to operational, competitive, and financial challenges outweighing its prospects. Read the full article on Seeking AlphaAnalisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Utili della società |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | -US$992m |
| Mar 31 2026 | n/a | n/a | -US$855m |
| Dec 31 2025 | US$13m | US$832k | -US$351m |
| Sep 30 2025 | n/a | n/a | -US$349m |
| Jun 30 2025 | n/a | n/a | -US$367m |
| Mar 31 2025 | n/a | n/a | -US$409m |
| Dec 31 2024 | US$11m | US$802k | -US$414m |
| Sep 30 2024 | n/a | n/a | -US$588m |
| Jun 30 2024 | n/a | n/a | -US$598m |
| Mar 31 2024 | n/a | n/a | -US$601m |
| Dec 31 2023 | US$1m | US$796k | -US$583m |
| Sep 30 2023 | n/a | n/a | -US$458m |
| Jun 30 2023 | n/a | n/a | -US$473m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$4m | US$791k | -US$417m |
| Sep 30 2022 | n/a | n/a | -US$400m |
| Jun 30 2022 | n/a | n/a | -US$376m |
| Mar 31 2022 | n/a | n/a | -US$370m |
| Dec 31 2021 | US$29m | US$765k | -US$347m |
| Sep 30 2021 | n/a | n/a | -US$323m |
| Jun 30 2021 | n/a | n/a | -US$301m |
| Mar 31 2021 | n/a | n/a | -US$264m |
| Dec 31 2020 | US$843k | US$141k | -US$222m |
Compensazione vs Mercato: La retribuzione totale di Rich ($USD 12.72M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 8.27M ).
Compensazione vs guadagni: La retribuzione di Rich è aumentata nonostante l'azienda non sia redditizia.
AMMINISTRATORE DELEGATO
Rich Adcock (57 yo)
Mr. Richard Gerald Adcock, also known as Rich, has been the President of ImmunityBio, Inc. since March 05, 2021 and serves as its Director since March 29, 2021. He has been the Chief Executive Officer of I...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.1b | |
| President | 5.8yrs | US$12.72m | 0.053% $ 4.1m | |
| Chief Financial Officer | 7.1yrs | US$4.24m | 0.028% $ 2.2m | |
| Chief Accounting Officer | 4.8yrs | US$745.31k | 0.011% $ 847.9k | |
| Chief Corporate Affairs Officer & Director | 5.4yrs | Nessun dato | 0.26% $ 20.5m | |
| Chief Technology Officer | 3.6yrs | Nessun dato | Nessun dato | |
| Chief Communications Officer & Head of Patient Advocacy | 6.4yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Human Resources | 5.1yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer of Liquid Tumors & Cell Therapy | 1.5yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 6yrs | Nessun dato | Nessun dato | |
| Chief Science Officer of Cellular | no data | Nessun dato | Nessun dato | |
| Senior VP of Product Development & Cell Therapy Program | 2.6yrs | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di IBRX è esperto e expertise (durata media dell'incarico 5.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 11.8yrs | US$12.29m | 27.5% $ 2.1b | |
| President | 5.4yrs | US$12.72m | 0.053% $ 4.1m | |
| Chief Corporate Affairs Officer & Director | 19.6yrs | Nessun dato | 0.26% $ 20.5m | |
| Independent Director | 6yrs | US$477.28k | 0% $ 0 | |
| Independent Director | 5.5yrs | US$470.59k | 0.00075% $ 58.2k | |
| Independent Director | less than a year | US$302.74k | Nessun dato | |
| Independent Director | 11.1yrs | US$513.38k | 0.025% $ 1.9m | |
| Lead Independent Director | 7.2yrs | US$514.19k | 0.012% $ 917.8k | |
| Independent Director | 5.4yrs | US$489.19k | 0% $ 0 |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di IBRX sono considerati esperti (durata media dell'incarico 6 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/08/07 13:41 |
| Prezzo dell'azione a fine giornata | 2026/08/07 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
ImmunityBio, Inc. è coperta da 7 analisti. 4 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Suranjit Mukherjee | BTIG |
| Justin Zelin | BTIG |
| Jason Kolbert | D. Boral Capital LLC. |